To stent or not to stent? Treating angina after ISCHEMIA —introduction
(Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research
To stent or not to stent? Treating angina after ISCHEMIA —why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial
(Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research
Decoding stroke risk scores in atrial fibrillation: still more work to do
(Source: European Heart Journal)
Source: European Heart Journal - April 6, 2021 Category: Cardiology Source Type: research
A most remarkable person: Dr Bernard Lown
(Source: European Heart Journal)
Source: European Heart Journal - April 5, 2021 Category: Cardiology Source Type: research
Powerful tributes to pioneering cardiologist Bernard Lown
Mark Nicholls speaks to Russian cardiologist Eugene Chazov and International Physicians for the Prevention of Nuclear War (IPPNW) co-President Ira Helfand about how Bernard Lown will be remembered as a cardiologist, educator, and peace activist (Source: European Heart Journal)
Source: European Heart Journal - April 2, 2021 Category: Cardiology Source Type: research
Hyperinflammation as underlying mechanism predisposing patients with cardiovascular diseases for severe COVID-19
It was already realized early in the COVID-19 pandemic that patients with cardiovascular disease, such as arterial hypertension, have a higher risk for an adverse course of COVID-19, raising the question of the underlying mechanisms.1 Furthermore, when it was described that the viral spike (S) glycoprotein mediates viral entry via binding to the angiotensin-converting enzyme 2 (ACE2),2,3 the question was raised whether therapies acting on the renin-angiotensin system, such as ACE inhibitors (ACEI) or angiotensin receptor blockers (ARBs), could affect the risk of infection or the clinical course of COVID-19. In a recent stu...
Source: European Heart Journal - April 2, 2021 Category: Cardiology Source Type: research
GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk
Comment on ‘Once-Weekly Semaglutide in Adults with Overweight or Obesity’ published in theNew England Journal of Medicine (doi:10.1056/NEJMoa2032183). (Source: European Heart Journal)
Source: European Heart Journal - April 2, 2021 Category: Cardiology Source Type: research
Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
(Source: European Heart Journal)
Source: European Heart Journal - April 1, 2021 Category: Cardiology Source Type: research
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Conclusion In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death. (Source: European Heart Journal)
Source: European Heart Journal - April 1, 2021 Category: Cardiology Source Type: research
Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation
(Source: European Heart Journal)
Source: European Heart Journal - April 1, 2021 Category: Cardiology Source Type: research
Corrigendum to: European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
[Eur Heart J (2019); doi:10.1093/eurheartj/ehy649]. (Source: European Heart Journal)
Source: European Heart Journal - March 31, 2021 Category: Cardiology Source Type: research
Erratum to: “ESC Core Curriculum for the Cardiologist”
Upon the original publication of this correction notice, the following requested author corrections to the original article “’ESC Core Curriculum for the Cardiologist’ Felix C Tanner, Nicolas Brooks, Kevin F Fox, Lino Gonçalves, Peter Kearney, Lampros Michalis, Agnès Pasquet, Susanna Price, Eric Bonnefoy, Mark Westwood, Chris Plummer, Paulus Kirchhof, ESC Scientific Document GroupEuropean Heart Journal, Volume 41, Issue 38, 7 October 2020, Pages3605 –3692,https://doi.org/10.1093/eurheartj/ehaa641”, were inadvertently not listed and not made. The Publisher would like to apologize for these omissions and has sinc...
Source: European Heart Journal - March 31, 2021 Category: Cardiology Source Type: research
A journey through clinic and research
I started to study Medicine at the University of Genoa, Italy more than 20 years ago and I now realize that I was quite far from understanding what ‘Medicine’ really means. After weeks and weeks spent on books during the first year, I understood that becoming a MD not only requires the willingness to help people with health problems, but also strong motivation and dedication to learn a huge amount of notions. In Italy, as it is the case for several other countries, the University courses last 6 years, during which the MD student is fully engaged by individual study, lessons and seminars, exercises, and internships. Wit...
Source: European Heart Journal - March 29, 2021 Category: Cardiology Source Type: research
Childhood-onset hypertrophic cardiomyopathy research coming of age
(Source: European Heart Journal)
Source: European Heart Journal - March 26, 2021 Category: Cardiology Source Type: research
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy
ConclusionPatients with childhood-onset HCM are more likely to have sarcomeric disease, carry a higher risk of life-threatening ventricular arrythmias, and have greater need for advanced HF therapies. These findings provide insight into the natural history of disease and can help inform clinical risk stratification. (Source: European Heart Journal)
Source: European Heart Journal - March 26, 2021 Category: Cardiology Source Type: research
